Morningstar® Fund Report™
BlackRock Global Funds – World Healthscience Fund (USD-RMB)
Performance History 30/06/2025
Growth of 1,000(CNY) Advanced Graph
Fund 11.29 3.39 4.25 4.91 -2.57
+/-Cat 5.61 11.04 -0.49 2.82 -3.32
+/-Idx 0.22 3.78 -1.43 0.75 -2.00
Category: Sector Equity Healthcare
Index: Morningstar Global Healthcare NR USD
Trailing Returns 04/07/2025
Fund +/-Idx
YTD -1.72 -1.51
3 Years 15.66 -2.78
5 Years 25.36 -1.28
10 Years 105.68 4.08
12 Month Yield 0.00
Dividend Paying Frequency -
Key Stats
Morningstar Category
Sector Equity Healthcare
Morningstar Rating™
ISIN
LU0122379950
NAV 04/07/2025
USD 66.4100
Day Change
0.20%
Total Net Assets (mil)
30/06/2025
USD 12529.53
Front Load Fee
3.00%
Deferred Load Fee
-
Manager Name
Xiang Liu
Erin Xie
Inception Date
06/04/2001
Benchmark
Fund Benchmark
MSCI World/Health Care NR USD
Morningstar® Benchmark
Morningstar Global Healthcare NR USD
Investment strategy
The Fund seeks to maximise total return and invest in a manner consistent with the principles of environmental, social and governance (“ESG”) investing. The Fund invests globally at least 70% of its total assets in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. Currency exposure is flexibly managed.
Portfolio Profile 31/05/2025
Morningstar Style Box®_Morningstar:
Equity Style
Asset Allocation %
% Long % Short % Net Assets
Stocks 97.56 0.00 97.56
Bonds 0.04 0.00 0.04
Cash 3.05 0.78 2.27
Other 0.14 0.00 0.14
Top 5 Regions %
United States 75.52
Europe - ex Euro 11.37
Eurozone 4.89
United Kingdom 4.39
Japan 1.69
Top 5 Sectors %
 Healthcare 97.56
 Basic Materials -
 Consumer Cyclical -
 Financial Services -
 Real Estate -
Top 5 Holdings Sector %
Eli Lilly and Co Healthcare Healthcare 6.85
AbbVie Inc Healthcare Healthcare 5.81
Johnson & Johnson Healthcare Healthcare 5.11
Abbott Laboratories Healthcare Healthcare 5.06
Boston Scientific Corp Healthcare Healthcare 4.89

Disclaimer and Important Notes:

  • Wealth Management Products are not deposits and have investment risks, and customers should be cautious in making any investment.
  • Structured Deposit is different from ordinary deposits and has investment risks, and customers should be aware of the investment risk and cautious in making any investment.
  • The relevant information and data displayed in the pages are for reference only and are those of the offshore funds, under Participation Non-Principal Protected Structured Investment Product, invested by QDII product-overseas fund series issued by DBS China, as well as of the onshore funds distributed by DBS China (as the case may be). Unless otherwise specified, all content in the webpages is provided by Morningstar Shenzhen Ltd (“Morningstar”), and it is possible to be modified without any notice. Some information provided by Morningstar to the pages may differ from the original data due to technical or operational reasons. DBS Bank (China) Limited (“DBS China”) has not verified, monitored or endorsed any content on any page and will not give any guarantee or warranty of whatsoever nature in respect of the correctness, completeness, or timeliness of any content on any page.
  • Nothing on this page shall constitute an offer or invitation or solicitation to subscribe any product or fund or to enter into any transaction. The content on this page does not have regard to the specific investment objectives, financial situation or particular needs of any specific person and is not intended to provide, and should not be relied upon for accounting, legal or tax advice, or investment recommendations and is not to be taken in substitution for the exercise of judgment by the reader, who should obtain separate legal or financial advice. DBS China does not act as an adviser or assume any fiduciary responsibility or liability for any consequences financial or otherwise.
  • Investment involves risks and the risk of loss from investment can be substantial. Opinions and estimates are subject to change without notice. Any past performance, projection, forecast or simulation of results is not necessarily indicative of the future or likely performance of any investment. Before entering into any transaction or making a commitment to purchase any product mentioned on this page, the reader should take steps to ensure that the reader understands the transaction and has made an independent assessment of the appropriateness of the transaction in the light of the reader’s own objectives and circumstances. In particular, the reader should read all relevant documentation pertaining to the product (including but not limited to product offering documents, term sheets, prospectuses or other similar or equivalent offer or issue documents, as the case may be) and may wish to seek advice from a financial or other professional adviser or make such independent investigations as the reader considers necessary or appropriate for such purposes. If the reader chooses not to do so, the reader should consider carefully whether any product mentioned in the webpages is suitable for him. DBS China shall not assume any liability for any loss or damage (whether direct or indirect) of any person arising out of or in connection with any error, omission, delay and/or reliance on any content of any page.